Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1993 Jul;25(1):6-19.
doi: 10.2165/00003088-199325010-00002.

Lomefloxacin clinical pharmacokinetics

Affiliations
Review

Lomefloxacin clinical pharmacokinetics

C D Freeman et al. Clin Pharmacokinet. 1993 Jul.

Abstract

Lomefloxacin is a quinolone antibiotic with chemical and microbiological properties similar to most commercially available agents of this class. There are differences, however, between lomefloxacin and other quinolones in activity against specific micro-organisms, a situation that is typical of most antibiotic classes. The pharmacokinetics of lomefloxacin support once- or twice-daily dosage, depending on the pathogen or site of infection. This is a result of its relatively high serum concentrations and long half-life. The outstanding pharmacokinetic features of lomefloxacin are its high degree of tissue distribution, lack of significant metabolism (and, therefore, no competitive drug interactions with other metabolised drugs showing a common metabolic pathway), and good oral absorption. Like most fluoroquinolones, lomefloxacin can chelate with heavy metals. However, this interaction can be eliminated by administering lomefloxacin 2h before the cation-containing products. Dosage adjustments are required in patients with renal dysfunction. However, patients with liver disease do not require alterations in lomefloxacin dosage regimens. The safety profile, lack of significant drug interactions and convenience of administration make lomefloxacin a useful agent in specific clinical settings.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Antimicrob Chemother. 1990 Oct;26 Suppl B:7-15 - PubMed
    1. Antimicrob Agents Chemother. 1989 Mar;33(3):283-90 - PubMed
    1. Antimicrob Agents Chemother. 1987 Jun;31(6):854-9 - PubMed
    1. J Antimicrob Chemother. 1984 May;13 Suppl B:9-23 - PubMed
    1. Antimicrob Agents Chemother. 1984 Dec;26(6):797-801 - PubMed

LinkOut - more resources